{"id":56292,"date":"2026-02-04T22:55:00","date_gmt":"2026-02-04T14:55:00","guid":{"rendered":"https:\/\/flcube.com\/?p=56292"},"modified":"2026-02-04T22:55:01","modified_gmt":"2026-02-04T14:55:01","slug":"cms-d017-gets-nmpa-approval-for-complement-mediated-kidney-disease-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56292","title":{"rendered":"CMS-D017 Gets NMPA Approval for Complement-Mediated Kidney Disease Study"},"content":{"rendered":"\n

China Medical System Holdings Limited<\/strong> (HKG:\u202f0867<\/a>) announced that the National Medical Products Administration (NMPA)<\/strong> has approved a clinical study for CMS-D017<\/strong>, a novel small\u2011molecule inhibitor of complement factor B, in healthy Chinese subjects. The drug is under development for kidney diseases mediated by complement dysregulation, including IgA nephropathy, idiopathic membranous nephropathy, lupus nephritis, and C3 glomerulopathy<\/strong>, and previously received approval for paroxysmal nocturnal hemoglobinuria (PNH)<\/strong> last month.<\/p>\n\n\n\n

Regulatory Milestone & Drug Profile<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>China Medical System Holdings Limited (HKG:\u202f0867)<\/td><\/tr>
Drug<\/strong><\/td>CMS-D017<\/td><\/tr>
Mechanism<\/strong><\/td>Small\u2011molecule inhibitor of complement factor B<\/td><\/tr>
Action<\/strong><\/td>Prevents abnormal activation of alternative complement pathway, reduces membrane attack complex damage<\/td><\/tr>
Indications<\/strong><\/td>Kidney diseases (IgA nephropathy, membranous nephropathy, lupus nephritis, C3 glomerulopathy); PNH<\/td><\/tr>
Approval<\/strong><\/td>NMPA Phase I clinical study authorization<\/td><\/tr>
Study Design<\/strong><\/td>Safety, tolerability, PK, PD in healthy Chinese subjects<\/td><\/tr>
Preclinical Data<\/strong><\/td>Excellent efficacy and safety demonstrated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Strategic Outlook<\/h2>\n\n\n\n